Migraine is a common neurological disorder involving repeated headaches and associated phenomena. It is a leading cause of disability throughout the world. It has a multifactorial background (genetic, environmental, metabolic, hormonal, pharmacological) and triggers that vary between patients.
However, it presents a common pattern of occurrence, with peak incidence in adolescence and peak prevalence in middle age. Recent research advances have helped to better determine the brain structures involved in migraine and observe physiological changes in patients with the disorder. These advances are the basis for studies of novel therapeutics and prophylactic approaches.
This report provides the current prevalent population for migraine across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Japan, China, India, Brazil) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the publisher's analysis team, several features of migraine patients, as well as the main symptoms of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main co-morbidities of migraine include:
Hypertension (depending on the study)
Mood disorders (anxiety, depression)
Obesity
Abdominal pain
Emesis
Cyclic vomiting syndrome (in children)
Multiple sclerosis
Reason to buy
Ability to quantify patient populations in global migraine market to target the development of future products, pricing strategies and launch plans.
Further insight into the prevalence of the subdivided types of migraine and identification of patient segments with high potential.
Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
Better understanding of the impact of specific symptoms on the prevalent population of migraine patients.
Identification of migraine patient sub-populations that require treatment.
Better understanding of the specific markets that have the largest number of migraine patients.
Key Topics Covered:
Introduction
Cause Of The Disease
Risk Factors & Prevention
Diagnosis Of The Disease
Variation By Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Comorbid Conditions / Features Associated With The Disease
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community. Aspire Health experienced a data security incident that may have involved personal and...
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...
Summary
Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...